vs
Orthofix Medical Inc.（OFIX）与Proto Labs Inc（PRLB）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是Proto Labs Inc的1.6倍（$219.9M vs $136.5M），Proto Labs Inc同比增速更快（12.1% vs 2.0%），Orthofix Medical Inc.自由现金流更多（$16.8M vs $8.4M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 3.3%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
Proto Labs是一家提供快速制造服务的企业，可通过3D打印、CNC加工、钣金加工以及注塑成型工艺，为客户生产用于原型制作和量产的定制零部件，产品广泛应用于医疗设备、航空航天、电子、家电、汽车、消费品等多个领域，公司总部位于美国明尼苏达州，在美国多地设有生产基地。
OFIX vs PRLB — 直观对比
营收规模更大
OFIX
是对方的1.6倍
$136.5M
营收增速更快
PRLB
高出10.1%
2.0%
自由现金流更多
OFIX
多$8.4M
$8.4M
两年增速更快
OFIX
近两年复合增速
3.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $136.5M |
| 净利润 | $-2.2M | — |
| 毛利率 | 71.1% | 44.2% |
| 营业利润率 | 0.2% | 5.0% |
| 净利率 | -1.0% | — |
| 营收同比 | 2.0% | 12.1% |
| 净利润同比 | 92.4% | — |
| 每股收益（稀释后） | $-0.05 | $0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXPRLB
| Q4 25 | $219.9M | $136.5M | ||
| Q3 25 | $205.6M | $135.4M | ||
| Q2 25 | $203.1M | $135.1M | ||
| Q1 25 | $193.6M | $126.2M | ||
| Q4 24 | $215.7M | $121.8M | ||
| Q3 24 | $196.6M | $125.6M | ||
| Q2 24 | $198.6M | $125.6M | ||
| Q1 24 | $188.6M | $127.9M |
净利润OFIXPRLB
| Q4 25 | $-2.2M | — | ||
| Q3 25 | $-22.8M | $7.2M | ||
| Q2 25 | $-14.1M | $4.4M | ||
| Q1 25 | $-53.1M | $3.6M | ||
| Q4 24 | $-29.1M | — | ||
| Q3 24 | $-27.4M | $7.2M | ||
| Q2 24 | $-33.4M | $4.5M | ||
| Q1 24 | $-36.0M | $5.3M |
毛利率OFIXPRLB
| Q4 25 | 71.1% | 44.2% | ||
| Q3 25 | 72.2% | 45.3% | ||
| Q2 25 | 68.7% | 44.3% | ||
| Q1 25 | 62.8% | 44.1% | ||
| Q4 24 | 69.0% | 42.7% | ||
| Q3 24 | 68.7% | 45.6% | ||
| Q2 24 | 67.8% | 45.0% | ||
| Q1 24 | 67.5% | 44.9% |
营业利润率OFIXPRLB
| Q4 25 | 0.2% | 5.0% | ||
| Q3 25 | -8.3% | 6.5% | ||
| Q2 25 | -7.9% | 3.7% | ||
| Q1 25 | -25.2% | 3.6% | ||
| Q4 24 | -5.3% | -1.2% | ||
| Q3 24 | -9.6% | 6.8% | ||
| Q2 24 | -12.5% | 4.8% | ||
| Q1 24 | -15.6% | 5.3% |
净利率OFIXPRLB
| Q4 25 | -1.0% | — | ||
| Q3 25 | -11.1% | 5.3% | ||
| Q2 25 | -6.9% | 3.3% | ||
| Q1 25 | -27.4% | 2.9% | ||
| Q4 24 | -13.5% | — | ||
| Q3 24 | -13.9% | 5.7% | ||
| Q2 24 | -16.8% | 3.6% | ||
| Q1 24 | -19.1% | 4.1% |
每股收益（稀释后）OFIXPRLB
| Q4 25 | $-0.05 | $0.25 | ||
| Q3 25 | $-0.57 | $0.30 | ||
| Q2 25 | $-0.36 | $0.18 | ||
| Q1 25 | $-1.35 | $0.15 | ||
| Q4 24 | $-0.76 | $-0.01 | ||
| Q3 24 | $-0.71 | $0.29 | ||
| Q2 24 | $-0.88 | $0.18 | ||
| Q1 24 | $-0.95 | $0.20 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $128.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $450.0M | $673.9M |
| 总资产 | $850.6M | $763.4M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OFIXPRLB
| Q4 25 | $82.0M | $128.1M | ||
| Q3 25 | $62.9M | $119.2M | ||
| Q2 25 | $65.6M | $103.2M | ||
| Q1 25 | $58.0M | $96.8M | ||
| Q4 24 | $83.2M | $103.1M | ||
| Q3 24 | $30.1M | $100.5M | ||
| Q2 24 | $26.4M | $112.9M | ||
| Q1 24 | $27.0M | $109.7M |
总债务OFIXPRLB
| Q4 25 | — | — | ||
| Q3 25 | $157.2M | — | ||
| Q2 25 | $157.0M | — | ||
| Q1 25 | $156.9M | — | ||
| Q4 24 | $157.0M | — | ||
| Q3 24 | $118.5M | — | ||
| Q2 24 | $118.0M | — | ||
| Q1 24 | $118.2M | — |
股东权益OFIXPRLB
| Q4 25 | $450.0M | $673.9M | ||
| Q3 25 | $442.5M | $664.7M | ||
| Q2 25 | $458.3M | $664.7M | ||
| Q1 25 | $458.3M | $656.8M | ||
| Q4 24 | $503.1M | $670.2M | ||
| Q3 24 | $525.9M | $680.0M | ||
| Q2 24 | $546.0M | $685.2M | ||
| Q1 24 | $570.3M | $687.3M |
总资产OFIXPRLB
| Q4 25 | $850.6M | $763.4M | ||
| Q3 25 | $832.6M | $756.9M | ||
| Q2 25 | $837.2M | $743.3M | ||
| Q1 25 | $823.1M | $737.5M | ||
| Q4 24 | $893.3M | $743.5M | ||
| Q3 24 | $867.9M | $753.8M | ||
| Q2 24 | $882.0M | $758.2M | ||
| Q1 24 | $906.0M | $769.8M |
负债/权益比OFIXPRLB
| Q4 25 | — | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.34× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.22× | — | ||
| Q1 24 | 0.21× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $16.5M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | $8.4M |
| 自由现金流率自由现金流/营收 | 7.6% | 6.2% |
| 资本支出强度资本支出/营收 | 4.9% | 5.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-1.3M | $59.7M |
8季度趋势，按日历期对齐
经营现金流OFIXPRLB
| Q4 25 | $27.7M | $16.5M | ||
| Q3 25 | $12.4M | $29.1M | ||
| Q2 25 | $11.6M | $10.6M | ||
| Q1 25 | $-18.4M | $18.4M | ||
| Q4 24 | $23.7M | $17.3M | ||
| Q3 24 | $11.7M | $24.8M | ||
| Q2 24 | $9.0M | $14.4M | ||
| Q1 24 | $-18.6M | $21.3M |
自由现金流OFIXPRLB
| Q4 25 | $16.8M | $8.4M | ||
| Q3 25 | $2.5M | $25.0M | ||
| Q2 25 | $4.5M | $9.1M | ||
| Q1 25 | $-25.1M | $17.1M | ||
| Q4 24 | $15.2M | $16.5M | ||
| Q3 24 | $6.3M | $23.2M | ||
| Q2 24 | $-360.0K | $10.2M | ||
| Q1 24 | $-29.1M | $18.8M |
自由现金流率OFIXPRLB
| Q4 25 | 7.6% | 6.2% | ||
| Q3 25 | 1.2% | 18.5% | ||
| Q2 25 | 2.2% | 6.7% | ||
| Q1 25 | -13.0% | 13.6% | ||
| Q4 24 | 7.0% | 13.5% | ||
| Q3 24 | 3.2% | 18.5% | ||
| Q2 24 | -0.2% | 8.2% | ||
| Q1 24 | -15.4% | 14.7% |
资本支出强度OFIXPRLB
| Q4 25 | 4.9% | 5.9% | ||
| Q3 25 | 4.8% | 3.0% | ||
| Q2 25 | 3.5% | 1.1% | ||
| Q1 25 | 3.5% | 1.0% | ||
| Q4 24 | 4.0% | 0.7% | ||
| Q3 24 | 2.7% | 1.2% | ||
| Q2 24 | 4.7% | 3.3% | ||
| Q1 24 | 5.6% | 2.0% |
现金转化率OFIXPRLB
| Q4 25 | — | — | ||
| Q3 25 | — | 4.03× | ||
| Q2 25 | — | 2.39× | ||
| Q1 25 | — | 5.11× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.44× | ||
| Q2 24 | — | 3.18× | ||
| Q1 24 | — | 4.05× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
PRLB
| CNC Machining Firstcut | $65.5M | 48% |
| Injection Molding Protomold | $47.6M | 35% |
| Three D Printing Fineline | $18.8M | 14% |
| Sheet Metal | $4.4M | 3% |
